Last updated: June 1, 2026
Executive summary
Tiagabine hydrochloride supply is concentrated in a limited set of international generic API manufacturers, with finished-dose availability typically handled by branded and generic drug product license holders in the US and other major markets. Reliable sourcing for tiagabine hydrochloride requires locking down (1) controlled API documentation (DMF/CEP, specs, impurity profile), (2) salt-form equivalence to tiagabine hydrochloride for dose-standardized formulations, and (3) country-of-origin and GMP compliance for export. Product-market access depends on whether the specific strength (tablets vs. other presentations where applicable) is currently commercially stocked and which ANDA applicants hold the active drug product rights.
What suppliers provide tiagabine hydrochloride API (active pharmaceutical ingredient)?
Featured snippet answer: Tiagabine hydrochloride API is supplied by a small group of specialty and generic API producers that support DMF-linked dossiers and export-scale GMP batches.
Common API sourcing routes
- GMP API direct purchase: Supplier ships tiagabine hydrochloride API against a purchased lot, with CoA, impurity reporting, and regulatory documentation.
- DMF-backed supply: Supplier supports US ANDA or other filings via referenced Drug Master File(s), often with pre-agreed specification sets.
- CEP-linked European supply: Some suppliers support alternative regulatory pathways through CEP documentation tied to manufacturing sites and controls.
Sourcing due diligence that matters for tiagabine hydrochloride
- Salt confirmation: Verifies that incoming material is tiagabine hydrochloride (not a freebase or alternate salt form).
- Assay and impurities: Impurity thresholds and analytical methods must match the target regulatory filing.
- Particle size and physical form controls: Affect blending and tablet uniformity for low-dose potency products.
- Supply continuity: Tiagabine API is a niche anticonvulsant API, so single-source risks are common.
Which companies manufacture tiagabine hydrochloride tablets (drug product) for the market?
Featured snippet answer: Drug product supply is handled by brand owners and generic drug product license holders that market tiagabine hydrochloride tablets at one or more strengths, with US distribution tied to current ANDA holders and stocking patterns.
Typical market structure
- US market: Generic access typically tracks ANDA approvals and patent status, with distribution by labeled drug product firms.
- International markets: Procurement often consolidates around local wholesalers and parallel distributors once generic supply is established.
What is the Orange Book status of tiagabine hydrochloride tablets?
Featured snippet answer: A complete Orange Book mapping requires the exact US NDC(s) and strength for tiagabine hydrochloride tablets, because listing granularity is per NDA and strength.
What to check on the Orange Book (for procurement and litigation risk)
- Patent numbers and listed expiration dates
- Exclusivity codes
- Method-of-use vs. formulation vs. device-relevant claims
- Whether any exclusivity blocks generic entry for a given strength
When do tiagabine hydrochloride products lose exclusivity and patent protection?
Featured snippet answer: Patent and exclusivity timelines are product- and strength-specific; tiagabine hydrochloride’s freedom-to-operate depends on the exact labeled formulation and NDA/ANDA lineage.
Commercial timing factors buyers track
- Regulatory exclusivity end dates: impacts the probability of reliable generic availability.
- Switch dates and label changes: sometimes affect distribution continuity even after legal exclusivity ends.
- Paragraph IV outcomes: can delay or accelerate generic stocking.
What formulations are protected for tiagabine hydrochloride, and how does that affect sourcing?
Featured snippet answer: For tiagabine hydrochloride tablets, IP coverage can include composition and formulation-related patents (excipients, manufacturing process, stability, and dissolution targets), which can constrain which manufacturers can source at parity.
Formulation and manufacturing variables that impact supplier qualification
- Tablet composition: excipient selection and proportion drives compatibility and release.
- Manufacturing method: granulation, compression conditions, and milling controls.
- Stability program: humidity and light sensitivity effects on shelf life.
- Bioequivalence implementation: requires matching dissolution behavior to the reference.
How do suppliers verify GMP compliance for tiagabine hydrochloride API?
Featured snippet answer: Supplier qualification relies on GMP inspection history, validated test methods, and controlled release testing aligned with the customer’s intended regulatory pathway.
Qualification checklist used in procurement
- GMP certificate for the specific site
- CoA includes:
- assay and uniformity-related metrics (if relevant)
- impurity panel results
- water content, residual solvents (as applicable)
- Method transfer compatibility for customer testing or release retesting
- Change control: notification and approval pipeline for process or analytical changes
What generic entry risks exist for tiagabine hydrochloride products?
Featured snippet answer: Generic entry risk is primarily driven by patent/exclusivity status and any supplier constraint that blocks ANDA or supplement approval. Execution risk rises when API supply is niche and single-sourced.
Risk categories buyers model
- Legal: Orange Book-listed patents that may delay approvals or trigger litigation.
- Supply: API shortages due to small supplier base.
- CMC: impurity drift, residual solvent variances, or dissolution deviations.
- Regulatory: warning letters or remediation plans that affect manufacturing availability.
What licensing deals govern tiagabine hydrochloride supply and drug product distribution?
Featured snippet answer: In the tiagabine space, licensing typically affects distribution rights and branded vs. generic exclusivity in specific territories, with ANDA approvals often determining manufacturing and labeling permissions.
What to map in licensing review
- Who holds the referenced NDA/ANDA
- Who manufactures under contract (API and finished dose)
- Whether supply is tied to exclusivity or termination clauses
- Whether patents impose manufacturing restrictions
Where is tiagabine hydrochloride manufactured and supplied geographically?
Featured snippet answer: API manufacturing is typically global (India, China, Europe, and other contract-capable regions), with drug product manufacturing distributed across US and Europe depending on licensing and ANDA geography.
Geographic procurement considerations
- Customs and controlled substance logistics: ensures stable lead times.
- Audit readiness: importers prioritize suppliers with consistent audit response.
- Local label compliance: strength and NDC-level product constraints.
How to build an actionable supplier shortlist for tiagabine hydrochloride
Featured snippet answer: A defensible shortlist uses regulatory documentation alignment, audit performance, and supply capacity checks rather than price alone.
Procurement-ready criteria
- Regulatory dossier support: DMF/CEP availability for the intended market.
- Site GMP performance: no unresolved compliance gaps affecting release.
- Technical package: CoA history, impurity trend reports, test methods.
- Capacity and lead times: confirms batch reproducibility and on-time distribution.
- Change control responsiveness: ensures predictable CMC lifecycle.
Key takeaways
- Tiagabine hydrochloride supply is constrained by a small set of GMP-qualified API manufacturers and by drug product rights that vary by strength and market.
- Supplier qualification for tiagabine hydrochloride should prioritize salt-form correctness, impurity profile alignment, and DMF/CEP-linked regulatory documentation.
- Product availability and procurement continuity are driven by strength-specific regulatory status (Orange Book/ANDA lineage), plus CMC execution and manufacturing-site compliance.
FAQs
- How do I verify tiagabine hydrochloride API is the correct salt form for my formulation?
- What documentation should accompany tiagabine hydrochloride API for US regulatory work?
- How do impurity specifications for tiagabine hydrochloride typically impact CMO selection?
- Do formulation or process patents for tiagabine hydrochloride tablets affect sourcing of generic drug products?
- What lead-time and supply-continuity indicators best predict shortages for niche anticonvulsant APIs?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Drug-specific pages).
